This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Other. Active years: 2018.
Company Filing History:
1 out of 834,453 Years Active: 2018
Title: The Innovative Contributions of Gary McLean
Introduction
Gary McLean is a notable inventor based in London, GB. He has made significant contributions to the field of immunology, particularly in the development of innovative solutions for combating rhinovirus infections. His work has implications for vaccine development and therapeutic strategies.
Latest Patents
Gary McLean holds a patent for the "Induction of cross-reactive cellular response against rhinovirus antigens." This invention involves an isolated peptide that comprises an amino acid sequence at least 90% identical to the VP4 amino acid sequence of a rhinovirus. Additionally, it includes an isolated polynucleotide encoding said peptide, which is placed under the control of elements necessary for its expression in a mammalian cell. The patent also covers a Th1 adjuvant when the immunogenic composition comprises one or more of the isolated peptides.
Career Highlights
Throughout his career, Gary McLean has worked with prominent organizations, including Sanofi Pasteur Inc. His expertise in immunology and peptide design has positioned him as a valuable contributor to the field. His innovative approaches have the potential to enhance vaccine efficacy and broaden the understanding of viral responses.
Collaborations
Gary has collaborated with notable colleagues such as Walton Ross and Sebastian Johnston. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.
Conclusion
Gary McLean's contributions to the field of immunology through his innovative patent and collaborations highlight his role as a significant inventor. His work continues to influence the development of effective strategies against rhinovirus infections.